These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 30207040

  • 1. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V.
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E.
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
    Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, Yarden A, Khazim K, Shehadeh N, Melzer Cohen C.
    Diabetes Obes Metab; 2024 Aug; 26(8):3058-3067. PubMed ID: 38680053
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
    Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V.
    Clin J Am Soc Nephrol; 2020 Dec 07; 15(12):1705-1714. PubMed ID: 33214158
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S, Williamson E, Pokrajac A, Fogarty D, Stirnadel-Farrant H, Smeeth L, Douglas IJ, Tomlinson LA.
    Diabetes Obes Metab; 2020 May 07; 22(5):847-856. PubMed ID: 31957254
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C, Kraut E, Whitlock RH, Komenda P, Woo V, Rigatto C, Tangri N.
    Am J Kidney Dis; 2020 Oct 07; 76(4):471-479.e1. PubMed ID: 32464161
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Cowan A, Jeyakumar N, Kang Y, Dixon SN, Garg AX, Naylor K, Weir MA, Clemens KK.
    Clin J Am Soc Nephrol; 2022 Jun 07; 17(6):835-842. PubMed ID: 35618342
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.